Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Immunovant CEO Matthew Gline said the company expects to launch brepocitinib by the end of September, pending FDA action. The company also reported enrollment in a phase 3 cutaneous sarcoidosis study and outlined anticipated second-half data readouts.
BRP said second-quarter revenue was $2.2 billion and normalized EBITDA was $139 million, with results ahead of expectations despite a $145 million net tariff impact. The company lifted full-year revenue and normalized EPS guidance.
BRP Inc files 6-K with SEC, disclosing material information. The filing is available for review.